Dicerna Pharmaceuticals, Inc.
(NASDAQ : DRNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.74%196.361.2%$606.64m
GILDGilead Sciences, Inc.
-0.27%67.830.9%$501.88m
CELGCelgene Corporation
-3.38%67.061.2%$476.71m
BIIBBiogen Inc.
0.33%320.251.3%$469.12m
ILMNIllumina, Inc.
-0.30%300.703.5%$380.58m
REGNRegeneron Pharmaceuticals, Inc.
-0.34%337.842.6%$297.66m
VRTXVertex Pharmaceuticals Incorporated
-0.91%159.601.9%$258.17m
ALXNAlexion Pharmaceuticals, Inc.
1.43%116.702.0%$201.91m
AAgilent Technologies, Inc.
7.35%67.211.5%$199.65m
SRPTSarepta Therapeutics, Inc.
1.79%118.4415.4%$149.39m
LGNDLigand Pharmaceuticals Incorporated
1.52%150.7923.3%$141.69m
EXASExact Sciences Corporation
-3.66%64.8225.3%$132.01m
TSROTESARO, Inc.
15.21%42.4314.4%$126.02m
NKTRNektar Therapeutics
-0.05%37.995.6%$122.18m
INCYIncyte Corporation
-1.34%63.392.5%$114.19m

Company Profile

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James C. Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.